Celecoxib for familial adenomatous polyposis

Onsenal is a new preparation of the COX-2 inhibitor celecoxib, indicated for use in familial adenomatous polyposis (FAP). Patients with this condition develop large numbers of intestinal polyps that overexpress COX-2. Left untreated, these polyps eventually progress to colorectal cancer.

In a randomised, controlled trial in 83 patients with FAP, treatment with celecoxib for 6 months reduced the number of polyps by a mean of 28% (compared with a mean reduction of 5% for placebo). Celecoxib has been studied only for up to 6 months in FAP, and has not been shown to reduce the risk of cancer or the need for surgery.

View Onsenal drug record

Further information: Pfizer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New once-weekly GLP-1 agonist for diabetes

New once-weekly GLP-1 agonist for diabetes

Ozempic (semaglutide) is a glucagon-like peptide-1...

Gluten-free prescribing restricted to bread and mixes

Gluten-free prescribing restricted to bread and mixes

GPs in England are no longer able to prescribe gluten-free...

New vitamin D deficiency thresholds recommended

New vitamin D deficiency thresholds recommended

The National Osteoporosis Society (NOS) has updated...

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...